5-HT2 antagonism and EPS benefits: Is there a causal connection?

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 35-39

  Kapur, Shitij ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Dopamine; Extrapyramidal symptoms; Parkinsonism; PET; Receptors; Schizophrenia; Serotonin

Indexed keywords

CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MIANSERIN; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; RITANSERIN; SEROTONIN 2 AGONIST; SEROTONIN 2 RECEPTOR; SETOPERONE; DOPAMINE 2 RECEPTOR; SEROTONIN ANTAGONIST;

ANIMAL MODEL; CATALEPSY; CLINICAL TRIAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTHESIS; MONKEY; NEUROANATOMY; NEUROPHYSIOLOGY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CLOZAPINE; HUMANS; RECEPTORS, DOPAMINE D2; RISPERIDONE; SEROTONIN ANTAGONISTS;

EID: 0029658331     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245603     Document Type: Review

References (50)

1. Arnt J, Hyttel J, Back-Lauritsen T (1986) Further studies of the mechanism behind scopolamine-induced reversal of antistereotypic and cataleptogenic effects of neuroleptics in rats. Acta Pharmacol Toxicol 59:319-324
2. 2-antagonist. Drug Dev Res 15:61-73
3. Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62:67-69
4. 2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13:500-506
5. Bethany S, Neal-Beliveau JN, Lucki J, Lucki I (1993) Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 265:207-217
6. 2-receptor antagonists can attenuate submaximal haloperidol-induced catalepsy in rats. Schizophr Res 15:153-154
7. Bouchard RH, Pourcher E, Filteau MJ, Baruch P (1994) Dose-related modulation of DA-dependant motor behavior by ritanserin (RIT) in idiopathic Parkinson's disease (IPD). Neuropsychopharmacology 20:210S
8. Casey DE (1989a) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology 99:S47-S53
9. Casey DE (1989b) Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 25:457-459
10. Casey DE (1994) Extrapyramidal syndromes: primate models as predictors of clinical response. Neuropsychopharmacology 20:370S
11. Ceskova E, Svestka J (1993) Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 26:121-124
12. Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PA (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology 85:329-332
13. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40
14. Dubovsky SL, Thomas M (1995) Serotonergic mechanisms and current and future psychiatric practice (review). J Clin Psychiatry 56:38-48
15. 1c antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 163:451-455
16. Farde L, Nordstrom AL (1992) PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry [Suppl.17]:30-33
17. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
18. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55:1-3
19. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15:19S-23S
20. Fuenmayor LD, Vogt M (1979) The influence of cerebral 5-hydroxy-tryptamine on catalepsy induced by brain amine depleting neuroleptics or by cholinomimetics. Br J Pharmacol 67:309-318
21. Gerlach J, Peacock L (1995) New antipsychotics: the present status. Int Clin Psychopharmacol 10 [Suppl 3]:39-48
22. Henderson J, Yiannikas C, Graham JS (1992) Effect of ritanserin, a highly selective 5-HT, receptor antagonist, on Parkonson's disease. Clin Exp Neurof 29:277-282
23. Hicks PB (1990) The effect of serotonergic agents on haloperidol-induced catalepsy. Life Sci 47:1609-1615
24. 2 antagonist, on Parkinsonian rest tremor. Curr Ther Res 41:298-300
25. Janicak P, Javaid J, Sharma R, Leach A, Easton M, Dowd S, Davis J (1994) Haloperidol Dose/Response relationship - Results from a random-assignment, double blind study. Neuropsychopharmacology 10 [Suppl.3]:106S
26. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
27. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57:PL103-PL108
28. Korsgaard S, Friis T (1986) Effects of mianserin in neuroleptic-induced parkinsonism. Psychopharmacology 88:109-111
29. Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118:245-252
30. Kostowski W, Gumulka W, Cxlonkowski A (1972) Reduced cataleptogenic effects of some neuroleptics in rats with lesioned midbrain raphe and treated with p-chlorophenylalanine. Brain Res 48:443-446
31. Leysen JE, Janssen PM, Megens AA, Schotte A (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55 [Supl]:5-12
32. 2 antagonists on haloperidol-induced dyskinesias in squirrel monkeys: no evidence for reciprocal 5-HT-dopamine interaction. Psychopharmacology 97:456-461
33. Maertens de Noordhout A, Delwaide PJ (1986) Opin pilot trial of ritanserin in parkinsonism. Clin Neuropharmacol 9:480-484
34. Maj J, Sarnek J, Klimek V, Rawlow A (1976) On the anticataleptic action of cyproheptadine. Pharmacol Biochem Behav 5:201-205
35. Marder SR, Meibach SR (1994) Risperidone in the treatment of schizophrenia. Am J Psychiatry 151:825-835
36. McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia: a controlled study of neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739-745
37. Meltzer H (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287
38. Meltzer HY (1995) The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 15:2S-3S
39. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
40. 2-dopamine receptor occupancy in relation to antipsychotic drug effects - a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
41. Peuskens J and the Risperidone Study Group (1995) Risperidone in the treatment of chronic schizophrenic patients: a multi-national, multi-centre, double-blind, parallel-group study vs haloperidol. Br J Psychiatry 166:712-726
42. Povlsen UJ, Noring U, Laursen AL, Korsgaard S, Gerlach J (1986) Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in Cebus monkeys. Clin Neuropharmacol 9:84-90
43. 2 receptor blocker. Drug Dev Res 8:205-211
44. 2 antagonists modulates the effects of D-2 dopamine receptor blockade. J Pharmacol Exp Ther 253:1162-1170
45. Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. Nature 284:472-473
46. Seeman P (1993) Receptors tables: drug dissociation constants for neuroreceptors and transporters. SZ Research, Toronto
47. Silver H, Blacker M, Weller MP, Lerer B (1989) Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 25:502-504
48. Stone CK, Garver DL, Griffith J, Hirschowitz J, Bennett J (1995) Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 152:1210-1212
49. Vidali M, Fregnan GB (1979) Effect of different CNS-active drugs on the catalepsy induced by neuroleptics. Curr Ther Res 25:544-556
50. Wadenberg ML (1992) Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in the rat. J Neural Transm [Gen Sect] 89:49-59